Skip to main content
. 2022 Aug 2;2(5):538–546. doi: 10.1016/j.jacasi.2022.04.008

Table 5.

Epidemiology of Asian PAH Registries

KORPAH70,71,a Lim et al48 PRO-KERALA47,a JHPAR72 Zhang et al49,b Jing et al50
Country South Korea Indonesia India Japan China China
No. of patients 625 148 2,003 189 276 956
No. of centers 35 1 50 8 5 9
Years enrolled 2008-2011 2003-2016 2015 2008-2013 2007-2009 2008-2011
Female, % 81 77 52 76 76 70
Mean age, y 47.6 ± 15.7 50.8 ± 15.9 56 ± 16.1 43.9 ± 16.9 36.4 36 ± 13
WHO subtype prevalence, n (%)
 
  • 2.
    PAH
    • 2.1.
      IPAH
    • 2.2.
      CTD-PAH
    • 2.3.
      CHD-PAH
    • 2.4.
      Other
 145 (23)
311 (50)
159 (25)		 44 (30)
36 (24)
53 (36)		 424 (21)
117 (28)
9 (4)
291 (69)		 105 (56)
48 (25)
16 (9)
20 9 (11)		 173 (63)
103 (37)
not applicable
not applicable		 335 (35)
182 (19)
411 (43)
not applicable
 
  • 3.

    PH-LHD

 not applicable not applicable 1,189 (59) not applicable not applicable not applicable
 
  • 4.

    CLD-PH

 not applicable not applicable 266 (13.3) not applicable not applicable not applicable
 
  • 5.

    CTPEH

 not applicable not applicable 77 (3.8) not applicable not applicable not applicable
 
  • 6.

    Miscellaneous

 not applicable not applicable 47 (2.4) not applicable not applicable not applicable

CLD = chronic lung; CTEPH = chronic thromboembolic pulmonary hypertension; JHPAR = Japan pulmonary hypertension registry; KORPAH = Korean registry of pulmonary arterial hypertension; LHD = left heart disease; PRO-KERALA = pulmonary hypertension registry of Kerala, India; other abbreviations as in Tables 1, 3, and 4.

a

Registry used echocargiographic criteria for inclusion rather than accepted right heart catheter parameters.

b

Includes only IPAH and CTD-PAH.